A PYMNTS Company

US: Pharmacies sue drugmakers for overcharging diabetes pill

By  |  December 3, 2019

Walgreens and three other pharmacy chains are suing drugmaker Bausch Health, its subsidiaries, and a separate generic drugmaker for allegedly colluding on a deal that allowed the brand-name companies to maintain a longer monopoly of the diabetes drug Glumetza. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to Reuters, the alleged deal resulted in those companies jacking up the price of the drug from US$350 to more than US$3,000 for a 30-day supply.

    The lawsuit, filed on Monday, December 2, alleges that Assertio and Lupin struck a deal with units of Bausch to delay the entry of their generic versions of Glumetza and allowed the companies to “maintain a monopoly” in the sale of the branded drug and its generic copies. 

    Albertson Companies and Kroger were among the other defendants.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.